



SYGNIS AG
Innovative Tools for
DNA Amplification and Sequencing

AGM, July 8th

Agenda

Report of the Company's development

Report on financial statements 2014

FY 2014 Highlights



Fiscal 2014

- First two SYGNIS SensiPhi®-based kits launched by QIAGEN
- Second licensing deal on parts of SYGNIS' Double Switch technology to SYSTASY Biosciences GmbH
- Introduction of new product and commercialization strategy
- First product line based on TruePrime™ technology for primer-free whole genome amplification
- First distribution agreement for future SYGNIS products signed – a lot more came beginning 2015

After period ended:

- Global launch of first products of the TruePrime™ family
 - TruePrime™ Single Cell WGA kit
 - TruePrime™ WGA kit
 - TruePrime™ RCA kit
- Global launch of second product line: SunScript™ Reverse Transcriptase (RT)
- Appointment of Dr. Miguel-Antonio Viribay as Vice President Sales & Marketing

2014 Key events

- February 2014: QIAGEN starts with the marketing activities to promote the two Sensiphi kits launched in December 2013.
- April 2014: we got enough data to support our PrimPol technology is good enough to compete against current WGA gold standard kits. No need of random primers.
- June 2014: due to the slow kit development with SensiPhi (licensed to QIAGEN), and due to the good results coming from PrimPol project, SYGNIS starts to analyze the possibility to develop their own final products with PrimPol.
- June 2014: Edison report sustains a valuation of 48M euros
- August 2014: GBC research publish a SYGNIS valuation report with a target valuation of 48M euros (after our change in our revenues guidance for 2014)

2014 Key events

- November 2014: GBC research publish a SYGNIS valuation report with a target valuation of 43M euros (after our change in our revenues guidance for 2014)
- December 2014: SYGNIS closed successfully a capital increase of 4,9M euros, with a share price of 2 euros per share. The capital increase was over subscribed.
- December 2014: the Company has paid back a loan given in 2013 by some external investors of 550k euros plus interest.
- December 2014: the Company announced its first distribution agreement with Biocat, as they will launch their first kit by January 2015
- After the increase of capital the new free float of SYGNIS AG is approximately 44%

2014 capital increase

- 2014 revenues were not in line with our estimations mainly due to the under expected performance of QIAGEN license agreement.
- Due to this and the supporting data with PrimPol, the Company moves from the license out strategy to final product development and commercialization strategy.
- To develop the new strategy of the Company, SYGNIS had to do a capital increase for the minimum amount needed to cover their new cash needs during 2015 and part of 2016.
- In order to avoid a strong dilution, the Company has confined itself to a small capital measure (the minimum amount required to implement their new strategy).
- During 2014 the Company used SEDA to cover their cash gaps during 2014 due to this change of strategy and bad performance on SensiPhi revenues (QIAGEN deal) The average price of the allocation of SEDA shares were 3,5 euros/share (higher than 2013 and 2014 capital increase)

2015 performance overview

- During Q1 of 2015 the Company is fulfilling successfully its business strategy by launching their new products. The market reaction has been very positive.
- Since December 2014 to today, the Company has signed 11 distribution agreements in Asia, EU and North America with key distributor leaders in the field.
- January 2015: The Company announced the launch of the single cell WGA kit based on TruePrime technology
- February 2015: the Company announced TruePrime WGA kit launching (regular one)
- March 2015: The Company announced SunScript RT kit launching
- March 2015: GBC research launch a short update with a valuation target of 54M euros.
- June 2015: The Company announced TruePrime RCA kit launching.
- Current market valuation of the company: approx. 40 M euros.

SYGNIS' Distribution Partner Network



SYGNIS Investor Relations

Conferences 2014	
January	JP Morgan Annual Healthcare Conference, San Francisco
May	BioEquity Europe, Amsterdam
May	17. Münchner Kapitalmarkt Konferenz, Munich
May	Bryan, Garnier Next Generation Sequencing (NGS) Conference, Paris
May	5. SCF – Small Cap Forum/Spring Conference , Frankfurt/Main
June	BIO International Convention, San Diego, USA
November	German Equity Forum, Frankfurt/Main
December	18. Münchner Kapitalmarkt Konferenz, Munich
Roadshows 2014	
May	Paris, Amsterdam, Frankfurt/Main, Munich
June	Düsseldorf
November	Frankfurt/Main, Stuttgart, Düsseldorf, Cologne
December	Hannover, Munich
Conferences 2015	
May	DVFA Spring Conference, Frankfurt/Main
May	19. Münchner Kapitalmarkt Konferenz, Munich
Roadshows 2015	
May	Frankfurt/Main
May	Munich

SYGNIS Media Coverage

BioCentury®

Sygnis Pharma AG (Xetra:LIO1), Heidelberg, Germany
Systasy Bioscience GmbH, Munich, Germany
 Business: Proteomics

Systasy acquired patents covering Sygnis' Split-TEV Double Switch technology. The IP is part of a broader IP family covering double switch technology, which qualitatively and quantitatively detects interactions of two proteins. The technology is based on the tobacco etch virus (TEV) protease, which Sygnis said has no targets in the human proteome and therefore does not cause any damage to mammalian cells. The protease can be used in its entirety (Full-TEV) or in a split version (Split-TEV) to detect protein-protein interactions in a "highly sensitive manner." Sygnis, which is retaining full rights to Full-TEV, said it is in "advanced negotiations" with potential partners to out-license Full-TEV for use in screening platforms and tests for the analysis of protein-protein interactions.

Systasy will use the Split-TEV technology under the brand name splitSENSOR to monitor individual drug targets in high throughput screening applications. Systasy will integrate splitSENSOR into its EXT assay technology for the simultaneous analysis of multiple cellular targets and signaling events within living cells. Sygnis will receive upfront payments and be eligible for royalties, but the companies are not disclosing further financial terms.

NEBENWERTE
 Journal

Anleger hoffen auf eine Wiederholung

Noch bis zum 04.12.2014 läuft die Bezugsfrist für die insgesamt 2.475.678 Aktien, die das Heidelberger Biotech-Unternehmen Sygnis für 2,- Euro je Aktie an den Mann bringen will. Ein Überbezug ist möglich, eine Privatplatzierung schließt sich an. Mit den knapp 5 Mio. Euro will Sygnis die Entwicklung des ersten Produkts für die Amplifikation von

KENNZAHLEN

	1H 2014	1H 2013
Umsatz	302.000	379.000
EBIT	-2,3 Mio.	-2,9 Mio.
Periodenergebnis	-2,4 Mio.	-2,9 Mio.
Ergebnis je Aktie	0,22	0,30
FK Quoten	50 %	39,5 %

DNA aus Einzelzellen anschauen. Die Produktentwicklung ist bereits für Januar 2015 geplant.

Zahlen typisch für Biotech
 Die 9M-Zahlen sind typisch für ein Biotech-Unternehmen. Die Erlöse stellten sich auf 302.000 (399.000) Euro. Der Verlust summierte sich auf -2,4 (-2,9) Mio. Euro bzw. -0,22 (-0,30) Euro je Aktie. Die Finanzierung läuft häufig über regelmäßige Kapitalerhöhungen, weshalb die EK-Quote mit 50 (39,5) % hoch ausfällt. Sygnis entwickelt zurzeit eine Serie von sogenannten TruePrime Kits, die in den Jahren 2015 und 2016 in den Markt eingeführt werden sollen. Die Vorteile dieser neuen Technologie sollen Forschern in unterschiedlichen Bereichen zugänglich



AM SONNTAG
€uro

Die Biotechfirma Sygnis kommt bei ihrer Neupositionierung gut voran. Vergangene Woche gab das Unternehmen bekannt, dass der Vermarktungspartner Qiagen begonnen habe, über seine weltweiten Vertriebswege die ersten beiden Sygnis-Produkte zu vermarkten. „Wir sind am Anfang einer Reihe von Markteinführungen“, sagt Vorstandschefin Pilar de la Huerta. Das deutsch-spanische Unternehmen, in dem die frühere Lion Bioscience aufgegangen ist, hat sich auf Tools für die DNA- und Proteinanalyse spezialisiert und sieht darin einen schnell wachsenden Markt. Die Börse reagierte euphorisch auf die Nach-

richt, die Aktie legte um mehr als 30 Prozent auf über acht Euro zu. Mit einem Börsenwert von 82 Millionen Euro ist das Unternehmen inzwischen sehr ambitioniert bewertet. Investierte Anleger sichern ihren Gewinn mit einem engen Stoppkurs ab.

Im Aufwind ist auch Syzygy, 2013 kletterte der Umsatz um 13 Prozent auf 35 Millionen Euro, der Gewinn je Aktie dürfte bei 0,29 Euro landen. Dieses Jahr soll es noch besser laufen. Der Spezialist für digitales Marketing erwartet einen Umsatzanstieg von 20 Prozent bei einer weiter verbesserten Marge. Der Wachstumsschub soll unter

boerse.ARD.de®

Sygnis entfacht Fantasie

Das Biotech-Unternehmen aus dem Prime Standard macht zwar noch immer mehr Verlust als sonst, sorgt traditionell die Hoffnung auf künftige Geschäfte für Kurssprünge. Und die ist bei Sygnis

Bereits im vergangenen Jahr hat Sygnis einen umfassenden Lizenzvertrag mit dem TecDax-K bereits Meilensteinzahlungen ausgelöst hat. Im ersten Halbjahr 2014 sollen nun auch Verkauf entwickelt Sygnis DNA-Amplifikationsprodukte, eine Technologie mit der die Zahl von DNA-A

Sygnis will sein Know-how in dem Bereich laut Vorstandschefin Pilar de la Huerta über weite "marktführenden Industriepartnern" in der molekularen Diagnostik und Wirkstoffforschung

Umsatz steigt, Verlust auch

In der Jahresbilanz 2013, die das Unternehmen am Montagabend ebenfalls präsentierte, kam niedrigem Niveau, ebenfalls ablesen. Dank der Kooperation mit Qiagen stiegen die Umsätze. Sie wären allerdings noch höher ausgefallen, hätte es nicht eine Verzögerung bei einem weit



Unter dem Strich verbuchte Sygnis einen Verlust von 3,2 Millionen Euro im Jahr zuvor. Die Aufwendungen für Forschung und Entwicklung im abgelaufenen Geschäftsjahr bei 2,2 Millionen Euro (na einer Kapitalerhöhung im Volumen von 3,1 Millionen Euro im C Liquidität per Jahresende von 0,6 auf 2,2 Millionen Euro erhöht. Unternehmen nun im kommenden Jahr 2015 zu erreichen.

In mein Depot

Aktie mit Schub

Die Sygnis-Aktie sprang bereits im Montagabendhandel um elf Prozent nach oben. Interessanten am dem Titel die Günstigkeit der Bilanz und die schwedische Bio-Unternehmen Genetrix und die Dievini Hopp Biotech

Capital
DEPESCHE

Tipp der Woche: Sygnis

Zu den Nebenwerten, die bislang nur wenigen Anlegern bekannt sind, gehört Sygnis. Das könnte sich in den kommenden Jahren ändern. Denn die Gesellschaft wandelt sich gerade vom Technologie- zum Produktunternehmen. Der Hersteller bio-technologischer Erzeugnisse mit Fokus auf Polymerasen (Enzyme für den Bereich der Aufbereitung und Analyse genetischer Informationen) verfügt über mehrere Projekte in unterschiedlichen Stadien. Eines der Hauptprodukte, SensiPhi, ist bereits seit Februar 2014 am Markt. Eine entscheidende Komponente hierfür war die Auslizenzierung an Qiagen – der im TecDAX notierte Spezialist für Proben- und Testtechnologien. Die Vermarktung eines weiteren

Produkts, TruePrime, ist ab 2015 geplant. Hierbei geht es um das Enzym PrimPol, das eine verbesserte Eigenschaft zur Vervielfältigung von beschädigtem oder konserviertem DNA-Material aufweist. Damit will Sygnis am dynamisch wachsenden Markt für Next Generation Sequencing (NGS) partizipieren. Aufgrund der noch frühen Vermarktungsphase der Produkte erwarten die Analysten von GBC für 2014 geringe Umsätze. Für 2015 rechnen wir mit einem deutlichen Anstieg der Vermarktungserlöse. Der Break-even dürfte 2016 erreicht werden. Den fairen Wert sehen die Analysten bei 4,05 Euro. Spekulative Anleger können die Kursdelle durch die Kapitalerhöhung zum Aufbau einer Position nutzen.

SYGNIS-Aktie: Mit Produktportfolio gut positioniert - Kaufempfehlung bestätigt! Aktienanalyse

4 investors

Sygnis: Lizenzdeal mit Systasy

Autor: Michael Barck

12.05.2014 (www.4investors.de) - Kursgewinne bei Sygnis-Aktien: Der Aktienkurs des Unternehmens liegt am Montagmittag bei 5,022 Euro mit 3,78 Prozent im Plus, nachdem die Gesellschaft Neuigkeiten zu einem Lizenzdeal mit der Systasy Bioscience GmbH bekannt gegeben hat. Gegenstand der Vereinbarung seien diverse Patente rund um die Double Switch Technologie, teilt Sygnis mit, nennt aber keine Details zur Höhe anstehender Zahlungen. Man erhalte eine Vorabzahlung sowie Lizenzgebühren, heißt es lediglich von Seiten des Unternehmens.

Sygnis will zudem weitere Partnerschaften abschließen. Man sei hierzu „in fortgeschrittenen Verhandlungen“ mit möglichen Kooperationspartnern aus dem Bereich Life Sciences und der pharmazeutischen Industrie, teilt das Unternehmen mit.

SYGNIS

Company long term Vision: A Glimpse into the Future



Mission

To research, develop, produce and sell novel enzymes and enabling tools for molecular biology applications, mainly for use in Next Generation Sequencing (NGS) and Single Cell Analysis (SCA)



Vision

To become a global leader in the development and commercialization of novel tools for users in molecular biology with special focus in NGS market.



Customers

Researchers in academia and industry, clinical and diagnostic laboratories, pharma and biotech through direct and distribution sales channels, OEM and license agreements for commercial applications.



Operations and S&M

International; lean professional team & experienced leadership with strong R&D, manufacturing, and enhanced product development as well as marketing capabilities.

Company Growth Drivers – Next Generation Sequencing (NGS)

Diagnostics and Personalized medicine

- Individualized treatments of patients based on genomic information requires a huge statistical data base to correlate individual genomic information with diseases, patients' drug response rates and risks of side effects.
- Develop new diagnostic tools based on genomic information.

Research Centres / Pharmaceutical industry

- Develop new and specific drugs depending on genomic information.
- Biomarker discovery and target validation.

Hospital and healthcare systems

- Early diagnosis of diseases.
- Disease prevention and monitoring of patients with genetic predisposition.
- Individualized treatments of patients based on genomic information.

Current market volume (2014)
NGS: ~\$2.5 B

Estimated growth rate
>23% p.a.


Thereof SYGNIS' market
NGS consumables: 30% – 40%

Source: MarketsandMarkets, September 2014

Company Growth Drivers – Single Cell Analysis (SCA)

SYGNIS is best positioned to address one of the fastest growing areas in molecular biology

Market development of Single Cell Analysis 2010 – 2016



Source: Enal Razvi's (SelectBio), October 2013

Increasing demand for single cell sequencing techniques

- Scientific awareness of cell to cell heterogeneity
- Launch of new more efficient platforms
- Number of scientific publications tripled over last three years
- Adoption of SCA into clinical laboratories
- Huge opportunities in oncology, neuroscience and stem cell research
- Method of the Year in 2013 (Nature Methods)

Genetic Profile: DNA

SYGNIS develops and markets innovative tools for DNA amplification and sequencing.



The genetic profile of a person is in the DNA of this person. So we need to study the DNA to obtain this information.

Steps that need to be done to study the DNA

The genetic profile of a person is in the DNA of this person. So we need to study the DNA to obtain this information.



Limited sample

Clinical sample (e.g. biopsies)

Irretrievable sample

Stored DNA

Analysis with need of higher amounts of DNA (e.g. NGS)



TruePrime® product line

Primer-free Whole Genome Amplification from rare samples down to single cells using proprietary TruePrime® technology



Enough DNA

for an almost unlimited number of tests and analysis

- Companion diagnostics
- Next Generation Sequencing
- SNP genotyping
- Clinical studies
- Patient genotyping


...

Genetic Profile: RNA

WHAT IS RNA?

RNA is one of the three major biological macromolecules that are essential for all forms of life along with **DNA** and **proteins**

GENETIC INFORMATION FLOW




CLINICAL ROLES

HUMAN DISEASES

Defects in certain RNAs or the regulation of RNAs have been implicated in a number of important **human diseases**:

- Heart disease
- Different types of cancer
- Stroke
- Muscular dystrophy
- Huntington disease
- Autism
- Deafness
- Susceptibility to diabetes
- ALS
- ...

SYGNIS Products cover critical Steps in typical NGS Workflows



TruePrime™ Product Line

The Revolution in Whole Genome Amplification

Technology behind: Combination of **TthPrimPol Primase** with **Phi29 Polymerase**
TthPrimPol to synthesize primers during reaction process
Phi29 to perform strand displacement and polymerization of DNA molecules

Available products today: TruePrime Single Cell WGA Kit
True Prime WGA Kit
more to come



Competitive advantages and customer benefits:

- No synthetic primers needed - complete absence of common artifacts linked to the use of oligonucleotides
- Reduced amplification bias in genome coverage
- Surpassing reliability
- Insensitive to external DNA (no amplification of potential DNA contamination)
- Exquisite reproducibility when DNA is amplified
- Superior sensitivity
- Easy to use
- Works perfectly well with all commonly used NGS platforms such as Illumina and Ion Torrent.

SunScript™ Product Line

Highly thermostable, ultra fast Reverse Transcriptase (RT)



RTs are enzymes to transcribe RNA information into DNA

- NGS -> gene expression profiling
- NGS, PCR in molecular diagnostics

Technology behind:

Novel proprietary engineered reverse transcriptase

- Derived from the well characterized HIV-1
- One of the most thermostable and fastest enzyme commercially available today

Competitive advantages and customer benefits:

- Highly thermostable: Active up to 85° C to resolve even the most complex RNA structures
- High reaction speed of >30 bases per second
- High yields of first strand cDNA
- Complete reverse transcription of very long RNA molecules
- High sensitivity
- Yields highly consistent and reproducible results

Licensed Products: SensiPhi®

SensiPhi® licensed to QIAGEN the world leading supplier of sample and assay technologies.

SYGNIS

Supplies
SensiPhi®



Product
revenues
Royalties



SensiPhi® is an essential part of
QIAGEN's REPLI-g® Kits



QIAGEN plans to replace standard Phi-29 polymerase
in their current amplification kits by SensiPhi®.

QIAGEN launched the first kits using SensiPhi® beginning 2014.


QIAGEN creates standards and addresses life science laboratories all over the world.

Pipeline: Double Switch


Fundamental technology for the detection of protein-protein interactions based on the full-length or split TEV protease.

- Strong, granted IP in Europe and the US.
- Enables construction of a broad range of assays of interest to basic scientists and the pharma industry.
- Big pharma companies that want to implement innovative screening platforms to look for new therapeutic targets, and drug screening service providers are the companies that could be interested in this screening platform.
- Patent transfer agreement for some patents linked to the Double Switch project with SYSTASY Bioscience GmbH signed in May.
- Out-licensing ongoing (non-exclusive approach), potential non-exclusive deals in a very advance situation.


Proprietary Product Launch Map for 2015



Proprietary Product Launch Map for 2016



SYGNIS Marketing Activities around Product Launches



- Establishing own SYGNIS Online Shop
<http://www.sygnis/shop>
- Extensive worldwide promotional mailing campaigns to potential users in the molecular biology field
- Presentations at key international scientific meetings and conferences in EU and the U.S.
 - US Advances in Genome Biology and Technologies (AGBT)
 - ACCR Annual Meeting 2015
 - EBMO/EMBL Symposia
- Special TruePrime™ webinar hosted by the inventor of this technology and scientific board member of SYGNIS, Prof. Luis Blanco
- Special TruePrime™ seminars done in worldwide known research institutions with the collaboration of Prof. Luis Blanco

SYGNIS' Growth Strategy

SYGNIS to become a key player in the development and commercialization of enabling DNA tools for DNA amplification and sequencing with focus on NGS and single cell analysis: Growth is a must!

INTERNAL

- Develop new polymerases and DNA tools based on proprietary know-how and technology.
- Leading innovation in NGS technologies and applications addressing new unmet market needs (epigenetic market).

EXTERNAL *

- **In the academic environment:**
Academic collaborations to generate innovative products and ideas.
- **In the industry:**
Companies or projects in the field of molecular diagnostic and/or DNA tools (including epigenetic field) that provides synergies and added value.

Product and
commercialization
strategy

SYGNIS will further develop own lines and products as well as new technologies addressing a multitude of applications for the amplification of various DNA or RNA species.

* SYGNIS will actively screen the markets for new projects

Summary



- Successful change in product and commercialization strategy
- On the way to become a leading company for products and technologies for DNA amplification and sequencing
- Addressing high growth markets in molecular biology including NGS and single cell analysis
- Broad distribution network with global partners cover most important geographical markets
- Full pipeline of innovative products to be launched during 2015 and 2016
- Appointment of Dr. Miguel-Antonio Viribay as Vice President Sales & Marketing to boost future sales especially in Europe and the U.S.
- Appointment of Mr. Sebastian Paul as Vice President of Finance & Administration
- On track to achieve break even in 2016

Key Advisors



Prof. Luis Blanco, X-Pol co-founder and shareholder

Co-discoverer of Phi29 DNA Polymerase (current worldwide gold standard for isothermal DNA amplification).
Over 100 published papers in international peer-reviewed journals.
Identified and characterized Phi29 Pol, Pol mu and Pol lambda.



Prof. Margarita Salas, X-Pol shareholder

Co-discoverer of Phi29 DNA Polymerase (current worldwide gold standard for isothermal DNA amplification).
Over 300 published papers in international peer-reviewed journals.
Member of The European Molecular Biology Organization (EMBO) and the USA Academy of Sciences.



Mr. Joseph Fernandez, advisor and Supervisory board member

Dr. Fernandez was one of two co-founders of Invitrogen, Inc., (Life Technologies now part of Thermo Fisher Scientific). He developed and helped launch the company's first commercial products, as well as all aspects of the company. In 1999, he founded Active Motif, which specializes in novel tools and platform technologies for genomics-driven cell biology and epigenetic pathway elucidation. He is the current chairman of the company.



Report on financial statements 2014

Key considerations Annual Accounts 2014

- First full financial year comparable to the previous year
- Clear reduction of operating costs (-24%), compared to 2013 mainly due to a decrease in R&D costs (-37%) as a result of the new strategy, as well as lower impairment losses (-52%)
- Clear improvement of result before tax (+25%)
- Successful capital increase of €4.9 million in December 2014, improvement of equity base and liquidity situation

Shortened profit & loss statement SYGNIS AG (HGB)

(in € thousand)	2014	2013	Change in %
Other operating income	85	135	-37,0
Personnel costs	384	415	-7,5
Other operating expenses	1.388	1.267	9,6
Financial result	-	49	n/a
Net result	-1.686	-1.587	6,2


Shortened balance sheet SYGNIS AG (HGB)

Assets (in € thousand)	31.12.2014	31.12.2013	Change in %
Shares in affiliated companies	32.539	30.374	7,1
Other assets	124	145	-14,5
Cash and securities	1.917	615	211,7
Total assets	34.580	31.134	11,1
Equity and liabilities (in € thousand)	31.12.2014	31.12.2013	Change in %
Equity and cash deposit	33.354	28.736	16,1
Provisions	370	519	-28,7
Liabilities to affiliated companies	703	1.777	-60,4
Other liabilities	153	102	50,0
Total assets	34.580	31.134	11,1


Shortened consolidated profit & loss statement (IFRS)

(in € thousand)	2014	2013	Change in %
Revenue	392	482	-18,7
Selling & administrative expenses	1.935	2.130	-9,2
Research & development expenses	1.413	2.231	-36,7
Other operating income	31	182	-83,0
Impairment losses	283	587	-51,8
EBIT	-3.208	-4.284	-25,1
Financial result	-137	-169	-18,9
Result before tax	-3.345	-4.453	-24,9
Net result	-3.480	-3.201	8,7

Shortened consolidated profit & loss statement (IFRS)



Shortened consolidated statements of cash flows (IFRS)



(in € thousand)	2014	2013	Change in %
Cash flow from operating activities	-3.579	-3.618	-1,1
Cash flow from investing activities	-621	-144	331,3
Cash flow from financing activities	5.439	5.507	-1,2

Shortened consolidated balance sheet (IFRS)


Assets (in € thousand)	31.12.2014	31.12.2013	Change in %
Intangible assets	1.678	1.634	2,7
Goodwill	5.942	5.942	0,0
Deferred tax assets	615	1.026	-40,1
Other non-current assets	184	187	-1,6
Cash and cash equivalents	3.764	2.196	71,4
Other current assets	354	342	3,5
Total assets	12.537	11.327	10,7

Equity and liabilities (in € thousand)	31.12.2014	31.12.2013	Change in %
Equity	8.342	5.954	40,1
Non-current financial liabilities	2.890	2.804	3,1
Deferred tax liabilities	-	288	n/a
Other liabilities	1.305	2.281	-42,8
Total assets	12.537	11.327	10,7

Shortened Q1 consolidated P&L Q1 2015 (IFRS)

(in € thousand)	Q1/2015	Q1/2014	Change in %
Revenue	76	64	18,8
Selling & administrative expenses	503	482	4,4
Research & development expenses	307	400	-23,3
Other operating income	13	7	85,7
Impairment losses	-	-	n/a
EBIT	-721	-811	-11,1
Financial result	-26	-40	-35,0
Result before tax	-747	-851	-12,2
Net result	-735	-840	-12,5

Shortened Q1 consolidated P&L Q1 2015 (IFRS)



Summary

- New strategy turned into action
- Successful capital increase December 2014
- First products launched to the market
- Distribution agreements signed for major markets
- Further product launches to come
- Improved financial results



Thank you for your Attention.



For more information, please contact:

SYGNIS AG

Pilar de la Huerta, CEO/CFO

Email: pdelahuerta@sygnis.es

Phone: +34 91 192 36 50